4DMT FY2025 net loss $140M; cash $514M; 4D-150 Phase 3 enrollment completed

4D Molecular Therapeutics, Inc.

Net loss of $140M in FY2025 versus $161M in FY2024; R&D expenses $196M (up from $141M).
Cash, equivalents and securities $514M; expected to fund operations into H2 2028.
4D-150 4FRONT-1 Phase 3 wet AMD enrollment completed; topline data expected H1 2027.
Otsuka partnership for 4D-150 in Asia-Pacific provided $85M upfront; up to $336M milestones plus royalties.
Leadership additions: new CFO Kristian Humer, CMO Julie Clark, CTO Katy Barglow, Board member Glenn Sblendorio.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

4D Molecular Therapeutics, Inc. reported year ended December 31, 2025 results: revenue $85 million.

Period: year ended December 31, 2025
Revenue: $85 million
Result: reported results

Exact text from the filing

role expanded to Chief Commercial & Business Officer • Entered Strategic Partnership with Otsuka Pharmaceutical Co., Ltd. for 4D-150 in Asia-Pacific Region o 4DMT received $85 million upfront cash payment in the fourth quarter of 2025 and expects to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities

View on SEC.gov

Browse all earnings releases →

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-113949

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.